Following the science to improve patient outcomes

We are entering an era of unprecedented potential to deliver scientific breakthroughs within asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and chronic cough.

Our overall research ambition for the future is to transform the lives of these patients through our growing portfolio of inhaled combinations at the core of care, biologics for the unmet needs of specific patient populations, and scientific advancements in disease modification with the ambition of achieving remission or even cures for patients.

Our Science

Our focus on unmet needs

We work in diseases where unmet medical need remains significant and, in some cases, where we see an increasing prevalence.


Asthma is a common chronic, inflammatory respiratory disease, which can cause breathlessness and wheezing - varying in severity and frequency. It affects the health and day-to-day lives of as many as 339 million individuals worldwide.

Idiopathic Pulmonary Fibrosis (IPF)

IPF is a severe progressive chronic respiratory disease which causes irreversible lung damage. IPF progression varies greatly between patients, but over time, most experience increased lung scarring and a gradual decline in lung function. There currently is no cure with survival rates of typically two to five years after diagnosis.

Chronic Obstructive Pulmonary Disease (COPD)

COPD is a progressive disease which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness - affecting an estimated 384 million individuals worldwide.

Chronic Cough

2020欧洲杯体育足球滚球比分Chronic Cough is often linked to inflammatory respiratory disease or reflux disease, but it can also be idiopathic with no recognised cause. For these patients, there are no effective treatments available. Chronic cough can have dramatic physical, social and psychological impact on patients’ lives.

New tools to tackle lung disease

Our overall ambition is to modify respiratory disease and ultimately cure. We believe we can do that by addressing the underlying biological drivers of the disease by focusing on four different mechanistic approaches: Lung Epithelium, Lung Immunity, Lung Regeneration and Neuronal Functions.

We have also expanded our toolbox of drug modalities beyond the more traditional small molecules and monoclonal antibodies, to allow us to target any novel biology we uncover, but also to access targets in the body that were previously seen as hard-to-reach.

Our People

2020欧洲杯体育足球滚球比分We have the bold ambition to evoke disease modification and cure in patients.

Maria Belvisi Senior Vice President and Head, RIA Innovative Medicines

Advancing Clinical Practice

Building on our 40-year heritage in respiratory disease, we now have the potential to fundamentally change clinical practice, and the way patients are treated and the outcomes they can receive.

Join Our Team

At AstraZeneca Respiratory, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. That difference starts with you. As one of Science Magazine’s 2018 Top Employer, we need people like you who share our passion for science and determination to meet patients’ needs around the world.

Our Pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval and may include assets that are now launched in one or more major markets.

Respiratory (as at 14 February 2020)

Phase I

Phase I

  • AZD0449 asthma
  • AZD1402 asthma
  • AZD5634 cystic fibrosis
  • AZD8154 asthma

Phase II

Phase II

  • abediterol asthma/chronic obstructive pulmonary disease
  • AZD7594 asthma/chronic obstructive pulmonary disease
  • AZD7986 chronic obstructive pulmonary disease
  • AZD8871 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • MEDI3506 chronic obstructive pulmonary disease and atopic dermatitis
  • tezepelumab atopic dermatitis
  • tezepelumab chronic obstructive pulmonary disease

Phase III

Phase III

  • Bevespi Aerosphere (PT003) chronic obstructive pulmonary disease
  • Breztri Aerosphere (PT010) chronic obstructive pulmonary disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • PT027 asthma
  • tezepelumab NAVIGATOR SOURCE severe uncontrolled asthma

LCM Projects

LCM Projects

  • Breztri (PT010) asthma
  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra OSTRO ORCHID (Japan/China) nasal polyposis
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma

Our Medicines

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations.

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.

Accolate, Accoleit, Vanticon


Bevespi Aerosphere

glycopyrronium/formoterol fumarate

Breztri Aerosphere

2020欧洲杯体育足球滚球比分budesonide/glycopyrronium/formoterol fumarate

Bricanyl Respules


Bricanyl Turbuhaler

2020欧洲杯体育足球滚球比分terbutaline in a dry powder inhaler



Duaklir Genuair


Eklira Genuair/Tudorza/Bretaris

2020欧洲杯体育足球滚球比分aclidinium, a LAMA



Oxis Turbuhaler

2020欧洲杯体育足球滚球比分Oxis Turbuhaler

Pulmicort Respules

budesonide inhalation suspension

Pulmicort Turbuhaler




Symbicort pMDI


Symbicort Turbuhaler


Our Resources

Veeva ID: Z4-17487

Date of next review: 07/06/2021